Clinical Trials
11 trialsNCT04543188 2025-10-23
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
Pfizer
Phase 1 Terminated
NCT04051827 2025-07-28
Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
Takeda
Phase 1 Completed
NCT03864042 2024-09-27
Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT01296555 2024-07-31
A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Genentech, Inc.
Phase 1 Terminated
NCT03420742 2023-01-27
A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors
Takeda
Phase 1 Completed
NCT02688088 2022-10-18
A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body
Eli Lilly and Company
Phase 1 Completed
NCT03291288 2021-05-14
Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)
Daiichi Sankyo
Phase 1 Completed
NCT01393990 2020-03-24
A Study of LY2228820 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02686164 2019-08-28
Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors
Eisai Inc.
Phase 1 Completed
NCT01209832 2019-03-18
A Tasisulam and Midazolam Drug Interaction Study in Cancer Patients
Eli Lilly and Company
Phase 1 Terminated
NCT00467779 2016-08-26
Study of Cobimetinib in Participants With Solid Tumors
Genentech, Inc.
Phase 1 Completed